Regado Biosciences (Regado Biosciences) Scaled Net Operating Assets : -0.10 (As of Jun. 2016)

View and export this data going back to . Start your Free Trial

What is Regado Biosciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regado Biosciences's operating assets for the quarter that ended in Jun. 2016 was $3.95 Mil. Regado Biosciences's operating liabilities for the quarter that ended in Jun. 2016 was $9.71 Mil. Regado Biosciences's Total Assets for the quarter that ended in Mar. 2016 was $55.83 Mil. Therefore, Regado Biosciences's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2016 was -0.10.

Regado Biosciences Scaled Net Operating Assets Historical Data

The historical data trend for Regado Biosciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regado Biosciences Scaled Net Operating Assets Chart

Regado Biosciences Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Scaled Net Operating Assets

0.23

0.42

0.37

-0.08

Regado Biosciences Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Scaled Net Operating Assets	Get a 7-Day Free Trial														0.22	-0.03	-0.06	-0.08	-0.10

Competitive Comparison of Regado Biosciences's Scaled Net Operating Assets

For the Biotechnology subindustry, Regado Biosciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regado Biosciences's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regado Biosciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Regado Biosciences's Scaled Net Operating Assets falls into.

Regado Biosciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regado Biosciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2015 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2015 )
=	(Operating Assets (A: Dec. 2015 )	-	Operating Liabilities (A: Dec. 2015 ))	/	Total Assets (A: Dec. 2014 )
=	(3.038	-	7.584)	/	54.397
=	-0.08

where

	Operating Assets		(A: Dec. 2015 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	65.469	-	62.431
=	3.038

	Operating Liabilities		(A: Dec. 2015 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	22.698	-	15.091	-	0.023
=	7.584

Regado Biosciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2016 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2016 )
=	(Operating Assets (Q: Jun. 2016 )	-	Operating Liabilities (Q: Jun. 2016 ))	/	Total Assets (Q: Mar. 2016 )
=	(3.949	-	9.707)	/	55.826
=	-0.10

where

	Operating Assets		(Q: Jun. 2016 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	44.641	-	40.692
=	3.949

	Operating Liabilities		(Q: Jun. 2016 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	24.883	-	12.629	-	2.547
=	9.707

Regado Biosciences Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Regado Biosciences's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Regado Biosciences (Regado Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regado Biosciences Inc (NAS:RGDO) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tobiratherapeutics.com

Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.

Executives

Domain Parters Vii L P	10 percent owner	ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Associates Domain	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p.	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Kim P. Kamdar	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Patrick J Heron	director	550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Dp Vii Associates Lp	10 percent owner	ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Jeffrey H Cooper	director	BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Frazier Healthcare V, Lp	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Christopher Peetz	officer: Chief Financial Officer	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Carol L Brosgart	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Regado Biosciences (Regado Biosciences) Headlines

No Headlines